

Table S1. Association between selective serotonin reuptake inhibitor use and the global Pittsburg Sleep Quality Index score and its subcomponents stratified by concurrent psycholeptic drug use.

	Number of measurements	Global PSQI score	Subcomponent PSQI					
			Sleep duration	Sleep onset latency	Sleep quality	Daytime dysfunction	Sleep disturbances	Sleep efficiency
		B in points (95%CI)	B in hours (95% CI)	OR (95%CI)	OR (95%CI)	OR (95%CI)	OR (95%CI)	OR (95%CI)
No psycholeptic drug use								
Non-SSRI use	12,840	Ref	Ref	Ref	Ref	Ref	Ref	Ref
SSRI use	292	-0.57 (-0.94; -0.20)	0.57 (0.40; 0.74)	0.93 (0.67; 1.30)	0.55 (0.36; 0.83)	1.37 (0.84; 2.24)	0.84 (0.45; 1.57)	0.68 (0.45; 1.01)
Psycholeptic drug use								
Non-SSRI use	1,473	Ref	Ref	Ref	Ref	Ref	Ref	Ref
SSRI use	166	-1.09 (-1.71; -0.47)	0.91 (0.65; 1.17)	0.78 (0.53; 1.16)	0.55 (0.36; 0.84)	1.59 (0.94; 2.68)	0.92 (0.51; 1.66)	0.68 (0.45; 1.04)

Global PSQI score and sleep duration are presented as B, representing higher = worse sleep or longer sleep duration. Other subcomponents are represented as odds ratio, representing higher = worse sleep. Adjusted for age, sex, educational level, employment status, body mass index, Center for Epidemiological Studies Depression Scale score and alcohol intake. Abbreviations: SSRI=Selective Serotonin Reuptake Inhibitor, PSQI=Pittsburg Sleep Quality Index, B= mean difference in study outcome between SSRI use versus non-use of antidepressants, OR= odds ratio, ref=reference group.